Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Integra Lifesciences Holdings (IART) Long-Term Debt Issuances (2016 - 2026)

Integra Lifesciences Holdings' Long-Term Debt Issuances history spans 15 years, with the latest figure at $49.7 million for Q4 2025.

  • On a quarterly basis, Long-Term Debt Issuances rose 40.4% to $49.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $720.7 million, a 48.14% increase, with the full-year FY2025 number at $720.7 million, up 48.14% from a year prior.
  • Long-Term Debt Issuances hit $49.7 million in Q4 2025 for Integra Lifesciences Holdings, down from $603.7 million in the prior quarter.
  • Over the last five years, Long-Term Debt Issuances for IART hit a ceiling of $603.7 million in Q3 2025 and a floor of $600000.0 in Q1 2021.
  • Historically, Long-Term Debt Issuances has averaged $71.9 million across 5 years, with a median of $12.5 million in 2021.
  • Biggest five-year swings in Long-Term Debt Issuances: crashed 99.65% in 2021 and later soared 3532.35% in 2024.
  • Tracing IART's Long-Term Debt Issuances over 5 years: stood at $12.0 million in 2021, then crashed by 46.06% to $6.5 million in 2022, then soared by 180.0% to $18.2 million in 2023, then soared by 94.51% to $35.4 million in 2024, then soared by 40.4% to $49.7 million in 2025.
  • Business Quant data shows Long-Term Debt Issuances for IART at $49.7 million in Q4 2025, $603.7 million in Q3 2025, and $12.9 million in Q2 2025.